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1. Introduction
Antimicrobial resistance (AMR) is one of the most 
relevant concerns of modern medicine worldwide: 
these drugs, considered as panacea for the treat-
ment of previously deadly infections are losing 
their eff ectiveness, resulting in increased mortali-
ty rate and decreased quality of life in the aff ected 
patient population [1,2]. The withdrawal of major 
pharmaceutical companies from the fi eld of anti-
microbial R&D means that healthcare profession-
als have to make due with the drugs that are al-
ready available [3,4]. In fact, one of the main re-
quirements for even the “Health for all by 2000” 
(World Health Organization, 1981) was the avail-
ability of eff ective antibiotics: therefore, one of the 
main setbacks of this program was the rapid glob-
al emergence of AMR [5,6]. The situation of antibi-
otic availability has not improved substantially 
since the beginning of the 21st century; in a current 
report from the WHO, the lack of novel antibiotic 
has once again been cited as a signifi cant threat to 
medicine [7]. Infections caused by resistant bacte-
rial pathogens are also sources of signifi cant fi -
nancial losses (both corresponding to increased 
expenses for the healthcare infrastructure and loss 
of profi ts from decreased productivity): in the 
United States, these fi nancial losses have been es-
timated to be around 50-60 billion US dollars, 
while in the European Union, these fi gures may 
go up as high as 1.5 billion euros [1,8].
Hungary ranks low in the total consumption of 
antibiotics (ABs) in Europe, both in the communi-
ty and in hospital sett ings (with a consumption of 
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15.4 and 1.18 defi ned daily doses [DDD] per 1000 
inhabitants per day, respectively, based on the lat-
est data of the ECDC [EU/EEA average: 21.9 and 
2.06 DDD per 1000 inhabitants per day, respec-
tively], however, the country is a leader in the 
consumption of broad-spectrum agents (predomi-
nantly fl uoroquinolones) instead of narrow-spec-
trum drugs [9,10]. The correlation between the 
levels of AB use (including self-medication with 
ABs) and the development and spread of resistant 
bacteria has been highlighted by several publica-
tions worldwide [11]. Although the relationship is 
complex, the increased utilization of ABs drives 
increases in resistance levels; therefore, the pru-
dent use of these agents is of utmost importance 
[12]. In addition to the responsibility of various 
healthcare professionals (HCPs) (i.e. the compli-
ance of prescribing physicians, pharmacists, nurs-
es with national and international guidelines and 
regulations, restriction of non-prescription AB 
sales, proper instructions given by HCPs [13-17]), 
the populations’ knowledge and att itudes on AB 
use and resistance has been shown to signifi cantly 
infl uence antibiotic consumption worldwide [18].
Apart from the knowledge of the general popu-
lation, the social aspects of AMR and improper 
antibiotic use are increasingly being recognized as 
an important facet of this issue: the insuffi  cient so-
cial awareness of antibiotic resistance may lead to 
exaggerated expectations for AB prescriptions 
from the public; in addition, the socio-economic 
status, education level, residential background, 
cultural factors, vulnerable population status, des-
perate need to maintain employment despite the 
presence of symptoms of bacterial diseases or dis-
crimination may all infl uence behavioural biases, 
health literacy and health-related decision-making 
processes in the general population [19,20]. These 
issues are usually addressed via awareness-rais-
ing and educational campaigns, both aimed at 
HCPs and the public. Among the campaigns with 
the largest impact, the European Antibiotic 
Awareness Day (EAAD; 18th of November) orga-
nized by the European Centers for Disease Con-
trol and Prevention (ECDC) and the World Antibi-
otic Awareness Week (18-24th of November in 
2019) by the WHO are among the most notable. 
Preceding research on the treatment-seeking 
behaviors and att itudes of the European popula-
tion has prompted our research interest to investi-
gate current trends in our local sett ing [21]. The 
aim of our present study was to assess the knowl-
edge level and att itudes of patients (general popu-
lation) towards AB and AMR, in addition to their 
practices towards the procurement and use of 
these drugs in the Szeged District of Hungary.
2. Materials and methods
2.1. Sample size and study location
A cross-sectional, questionnaire-based pilot study 
was performed among patients aged 18 years or 
older in the Szeged District. The Szeged District is 
located in Csongrád County, in the Southern 
Great Plain of Hungary; with an area of ~741 km2, 
it is the second largest district in the county, con-
taining thirteen inhabited places (ten villages, one 
large village and two cities). The population of the 
county is around 204,000 people, as per most re-
cent census data (population density: 276/km2). 
The study population comprised of adult pa-
tients att ending their general practitioner’s (GP) 
offi  ces in the District. Sample size for the adult 
population of the Szeged District was calculated 
by using the Raosoft sample size calculator [22], 
based on the formula below (1): population was 
N=169,300 (83% of the total population is aged 18 
or older, as per most recent census data), x was 
confi dence interval of 95%, E was the a margin of 
error set at 5% and the expected response rate set 
at 50%, based on the results of the Special Euroba-
rometer 407 [21]. The minimum sample size of 
n=103 (n=94 with an added contingency of 10% for 
non-responders and inappropriate responses) was 
set for the completion of this pilot survey.
n=N (N-1)E2+x
x
 (1)
A total of 218 patients in fi ve GPs’ offi  ces 
throughout the Szeged District were approached 
with our questionnaire, out of which 113 chose to 
participate in our survey (corresponding to a re-
sponse rate of 51.9%, females were more inclined 
to participate). Four respondents (1.5%) were ex-
cluded due to incompletely fi lled out question-
naires; therefore n=109 were included in the fi nal 
analysis. 
2.2. Structure of the questionnaire
A literature review of similar surveys was con-
ducted in the PubMed/MEDLINE database in or-
der to identify potential questions for the develop-
ment of the instrument in this study; in addition, 
some of the questions were based on the questions 
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of the Eurobarometer Survey 407 [21]. The ques-
tionnaire was adapted in accordance with local 
population characteristics and the questionnaires 
were developed in Hungarian language. The ques-
tionnaire was then reviewed and assessed by 
three faculty members (with extensive experience 
in survey research), a GP, a community pharma-
cist and a public health specialist for content and 
face validation and to ensure the clarity and ease 
of use during the survey. Minor modifi cations (re-
wording, reformatt ing or reordering of questions) 
were performed based on the comments of the 
evaluation panel. 
The fi nal structured questionnaire consisted of 
33 questions covering three major areas: Part I. de-
mographic characteristics and health status (nine 
items: age, sex, highest level of education, place of 
residence, employment status, subjective evalua-
tion of health status, existence of chronic illnesses, 
reason for present GP-visit); Part II.: questions 
about the use and the procurement of ABs and the 
roles of HCPs in the eyes of the respondents (four-
teen items); this section included single-choice, 
multiple-choice and open-ended questions, re-
spectively. In addition, some of the questions had 
follow-up questions, therefore respondents were 
asked to fi ll out or skip specifi c questions depend-
ing on their answers; Part III.: questions on the 
knowledge and att itudes of the patients (fi ve-fi ve 
items each), adopted from the Eurobarometer sur-
vey: at the statements evaluating the respondents’ 
knowledge on ABs, they had the option of choos-
ing between ‘True’, ‘False’, and ‘I don’t know/Un-
sure about the answer’, while during statements 
aiming to measure the att itude of respondents, a 
fi ve-point Likert-scale ranging from “Strongly 
agree” to “Strongly disagree” was used to record 
the responses of the participants. Questions QK1-
QK4 (see Table 3) were used to create a composite 
knowledge-score (ranging between 0-4 for each 
correct statement) to allow for comparison with 
the results of the Eurobarometer surveys.
2.3. Data collection, statistical analysis
Data collection for the survey was running be-
tween January 2016 and January 2018. Prior to par-
ticipating in the survey, the nature and purpose of 
the study was explained to the patients, including 
the data collection methods and that participation 
was voluntary. Participants were informed that 
the data collection, processing and analysis are 
anonymous. Data collectors also made sure that 
the patients did not participate in the Eurobarom-
eters regarding ABs in parallel (Special Euroba-
rometer 445: fi eld work between April-May 2016; 
Flash Eurobarometer 444: fi eld work between Sep-
tember-October 2016, respectively) [23]. No renu-
meration or gifts were given to participants to fa-
cilitate them to take part in the survey. 
All questionnaires were checked manually and 
questionnaires with >90% completion were includ-
ed in the analysis. All the completed question-
naires were entered into Epi-data version 3.1 and 
the data was exported to SPSS (Statistical Package 
for the Social Sciences) Statistics version 23.0 (IBM; 
Chicago, IL, USA) for data analysis. Descriptive 
statistics were used to analyze qualitative vari-
ables, while quantitative variables were summa-
rized using mean ± standard deviation (±SD). Uni-
variate analysis was performed using Pearsons’s 
Chi-squared tests or Fisher’s exact tests when 
comparing proportions, while Student’s t-tests 
were utilized to assess the association between nu-
merical values. All statistical tests were two-tailed, 
and results were considered to be statistically sig-
nifi cant if p<0.05.
2.4. Ethical approval
The survey was conducted in accordance with the 
Declaration of Helsinki and national and institu-
tional ethical standards. Ethical approval for the 
study protocol was obtained from the Regional 
and Institutional Human Medical Biological Re-
search Ethics Committ ee of the Szent-Györgyi Al-
bert Clinical Centre, University of Szeged (regis-
tration number: 3688).
3. Results
3.1. Demographic characteristics, health status of 
respondents
The socio-demographic characteristics of the re-
spondents are presented in Table 1. The median 
age of the respondents was 51 years (50.8±17.8 
years, range: 19-93). The majority of respondents 
were from the seat of the district and the county 
(Szeged; n=62; 56.9%), while other respondents 
were from villages (43.1%; Domaszék n=41, 
Szatymaz n=2, Deszk, Kistelek, Kiskundorozsma, 
Zákányszék n=1, respectively). Among the respon-
dents, females (60.6%) and patients with the sec-
ondary-level education (61.5%) were represented 
in higher numbers.
Acta-2001.indb   7 6/8/20   4:09 PM
8 Acta Pharmaceutica Hungarica DOI:  10.33892/aph.2020.90.5-14
The respondents evaluated their current health 
status as bad in 9.3% of cases (2.8% and 6.5% for 
very bad and bad, respectively), while 41.7% re-
sponded with moderate and 51.9% with good 
(46.3% and 5.4% for good and very good, respective-
ly) 53.7% (n=59) reported having a chronic illness 
which requires medical att ention/pharmacothera-
py (or has required therapy in the last 12 months): 
51.7% of these patients reported one chronic dis-
ease, while 31.2%, 13.7% and 3.4% reported suff er-
ing from two, three and four chronic ailments re-
spectively. The self-reported chronic illnesses 
were diseases of the cardiovascular system 
(30.4%), diabetes (type I and II; 21.8%), diseases of 
the locomotor system (16.3%), endocrine system 
(7.6%), pulmonary system (7.6%), kidney disease 
(5.4%), gastrointestinal system (5.4%), autoim-
mune disorders (2.2%), psychiatric disorders 
(2.2%) and malignant illness (1.1%). A signifi cant 
association was found between the self-reported 
health status and the presence of chronic illnesses 
(p<0.0001), but not between age and chronic ill-
nesses (p>0.05).
36.0% of respondents have visited the GPs’ of-
fi ce to procure a prescription for themselves or 
their family members, 31.3% due to an acute ill-
ness, 19.6% were on their follow-up visit, 5.5% 
came for the administration of a medicine or vac-
cine, 4.8% visited for a routine check-up (for em-
ployment purposes or for driving licenses), while 
2.8% came for a referral lett er to visit a specialist.
3.2. Antibiotic use, sources of antibiotics 
80.7% (n=88) of respondents stated that they visit 
the GPs offi  ces 0-2 times a year due to an infec-
tious disease, while 14.7% (n=16) reported 3-4 and 
4.6% (n=5) reported more, than 4 occasions, re-
spectively. Patients were surveyed on the last time 
they took ABs (results are presented in Table 2): al-
most one-third (32.1%) has taken these drugs dur-
ing the last 12 months. 90.5% (n=99) of respon-
dents has obtained their last course of ABs 
through a medical prescription, 1.9% (n=2) had it 
administered by a medical practitioner, 4.8% (n=5) 
used leftover drugs from a previous course of 
therapy, while 2.8% (n=3) obtained it from a phar-
macy, without a medical prescription.
By their own admission, 31.6% of respondents 
stated that the last time they took ABs was to treat 
sore throat, while 14.0% has taken them for a uri-
nary tract infection, 13.2% to treat a cold, 7.4% for 
bronchitis, 6.6% to treat a fl u or a persistent cough, 
5.1% for pneumonia, 4.4% took it prophylactically 
after surgery, 2.9% took them after a dental proce-
dure, 2.2% took them due to a skin and soft tissue 
infection or to treat diarrhoea and 1.5% took ABs 
to alleviate fever. 
Patients were asked about their sources of infor-
mation on ABs (multiple answers were allowed): 
medical doctors were perceived as the most trust-
worthy sources (70.6%), followed by community 
pharmacists (23.9%), the Internet (20.2%), previous 
secondary school/university education (19.3%), 
television and/or radio (18.3%), books, newspapers 
or information pamphlets (17.4%), family mem-
bers (10.1%), friends or acquaintances (7.3%), other 
Table 1 Demographic characteristics of the participants
Characteristics n (%)
Gender
Female 66 (60.6%)
Male 43 (39.4%)
Age  
18-35 years 27 (24.4%)
36-64 years 50 (45.8%)
65 years or older 32 (29.8%)
Place of residence  
Urban 62 (56.9%)
Provincial 47 (43.1%)
Level of education
Elementary school 12 (11.0%)
Trade school 28 (25.7%)
Secondary school 18 (16.5%)
Grammar school 21 (19.3%)
College/University 30 (27.5%) 
Employment status
Employed 50 (45.9%)
Unemployed/Looking for a job 6 (5.5%)
Pensioner 38 (34.9%)
Rehabilitation 2 (1.8%)
Disability pension 3 (2.7%)
Childcare benefi t/allowance 3 (2.7%)
Student 7 (6.5%)
Table 2 Responses to the question ‘When was the last time 
you took antibiotics?’
Last use of antibiotics n (%)
I have never taken antibiotics. 4 (3.7)
More than 5 years ago. 20 (18.3)
1-5 years ago. 29 (26.6)
In the last 12 months. 35 (32.1)
In the last month. 10 (9.2)
I am currently taking antibiotics. 5 (4.6)
I don’t know/I don’t remember. 6 (5.5)
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healthcare-professionals, e.g., pharmacy assistants, 
nurses, health-promotion specialists (2.8%) and 
other sources (e.g. medicines information leafl et; 
1.8%). There were no signifi cant association be-
tween age or gender  and the reported source of 
information (p>0.05). One third of patients (34.9%; 
n=38) have recalled receiving information about 
not taking antibiotics unnecessarily: most of these 
respondents got this information from their physi-
cians (55.9%), in addition, community pharma-
cists, family members (11.8%, respectively), the In-
ternet (8.8%), friends or acquaintances and the In-
ternet (5.9%) were also identifi ed. 88.2% (n=30) of 
these patients chose to take this advice seriously. 
Older patients recalled receiving information on 
this topic much less frequently (p=0.021).
In addition, patients were asked about their ad-
herence to the medical advice from their respec-
tive HCPs: 65.1% stated that they always and com-
pletely follow the instructions of the physicians, 
while 33.9% stated that they generally take these 
instructions into account; complete adherence to 
the instructions of the community pharmacists 
was reported in 45.5%, while generally good ad-
herence in 47.5% of respondents. Only a minority 
of respondents (0.9% regarding physicians’ and 
7.1% for pharmacists’ instructions) stated that 
they generally do not follow the instructions of 
their respective healthcare-providers. 73.1% (n=79) 
considered the purchase of additional medications 
or adjuvants (e.g., probiotics) with antibiotics if 
the pharmacist recommends it. 4.6% (n=5) of pa-
tients reported trying to obtain antibiotics from a 
community pharmacist without a prescription, 
bypassing their physicians; 1.8% (n=2) of respon-
dents successfully obtained these drugs from a 
pharmacy. Additionally, 17.8% agreed (5.9% , 
7.9% ), that they would be able to source antibiot-
ics without a medical prescription, if there were a 
need for it (53.5% and 22.8%  with this statement, 
while 9.9% was  of the answer). This was more 
prevalent in respondents from Szeged (p=0.023), 
than from respondents from surrounding villages.
3.3. Knowledge and att itude about antibiotics, socio-
demographic and key variable analysis
The responses for the knowledge-based questions, 
adapted from the Eurobarometer survey are pre-
sented in Table 3. 18.3% (n=20) of respondents gave 
correct answers to all relevant questions (QK1-
QK4), while 7.3% (n=8) had zero correct answers; 
the highest number of respondents could answer 
two questions (43.1%; n=47) correctly. The average 
number of correct answers overall were 2.11±1.16; 
there were no statistically signifi cant diff erences 
among the results of respondents from Szeged 
(2.27±1.10) and respondents from the surrounding 
villages (1.89±1.19; p>0.05). Similarly, no correla-
tion was found between the number of correct an-
swers and age, current health status, presence/ab-
sence of chronic illness, employment status or 
number of GP visits per year (p>0.05). There was, 
however, association found with the highest level 
of education (p<0.001); the same association was 
also found when considering the number of cor-
rect answers to QK5 (p=0.029). In addition, re-
spondents who reported to use antibiotics for in-
appropriate indications (e.g., sore throat, cold, fl u, 
fever) had worse results in the knowledge-based 
questions (QK1-4 p=0.03; QK5 p=0.047).
The respondents’ beliefs regarding ABs and 
prevention (questions QA1-5) are summarized in 
Table 4. Of note, 75% of respondents believe that 
ABs are medicines of special importance (QA1); 
there was no correlation between this positive 
Table 3 Statements measuring respondents’ knowledge on ABs
True
n (%)
False
n (%)
Unsure of the 
answer
n (%)
QK1 Antibiotics are eff ective against viruses. 
(Correct answer: False) 56 (51.4%) 35 (32.1%) 18 (16.5%)
QK2 Antibiotics are eff ective therapy for the common cold and the fl u. 
(Correct answer: False) 50 (46.3) 43 (39.8%) 15 (13.9%)
QK3 Unnecessary and inappropriate (in dose or duration) use of antibiotics 
makes them become ineff ective. 
(Correct answer: True)
86 (78.9%) 7 (6.4%) 16 (14.7%)
QK4 Taking antibiotics often has side-eff ects such as diarrhea.
(Correct answer: True) 74 (65.1%) 17 (15.6%) 21 (19.3%)
QK5 When my symptoms are gone, I may stop taking the antibiotic safely.
(Correct answer: False) 38 (34.8%) 65 (59.6%) 6 (5.6%)
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statement and the participant’s age, gender or the 
number of correct answers (see previous section), 
however, participants with higher levels of educa-
tion (p=0.048) and those, who reportedly visit the 
GP’s offi  ce more frequently due to infections ail-
ments (p=0.021) were more likely to have such be-
liefs. Only 64.8% of the respondents regarded 
their knowledge about infectious diseases as ap-
propriate (QA2). Interestingly, women were more 
satisfi ed with their knowledge-level (p<0.001), 
while satisfaction-level and the number of correct 
answers showed no association (p>0.05). In a simi-
lar fashion, women were more likely to be dissat-
isfi ed with the involvement of the media in dis-
seminating relevant information on infectious dis-
eases to the public (QA5; p=0.024); although 44.9% 
agreed and 39.3% of the patients disagreed with 
the statement. All respondents agreed on the role 
of personal hygiene and personal care (100%) in 
infectious disease-prevention, however, the role of 
vaccines in this regard was clear to only 77.8% of 
participants (QA3 and QA4, respectively).
4. Discussion
In the present study, the knowledge level and att i-
tudes of patients towards ABs and antibiotic resis-
tance, in addition to their drug utilization practic-
es were assessed in the Szeged District of Hunga-
ry. We have found that around 32% of respondents 
have taken ABs in the last 12 months, mainly for a 
sore throat. They identifi ed healthcare profession-
als as the most trustworthy sources of informa-
tion, moreover they generally follow their advices; 
while the Internet also emerged as an important 
information source, verifying the results of previ-
ous reports [24]. Just minority (4.8%) used leftover 
ABs for their last course, and 2.8% accessed to 
non-prescribed ABs from a pharmacy. This latt er 
is in line with the result of a European study, 
where 1-9% of the population was identifi ed gen-
erally to obtain ABs without a prescription from a 
pharmacy [25]. Regarding the knowledge level of 
the respondents, we have found that most patients 
were aware of the emergence of bacterial resis-
tance and the potential adverse events that may 
occur during AB use, however, many respondents 
identifi ed colds, the fl u and viral infections in gen-
eral as indications for AB therapy. Based on our 
results, correlation was found between the highest 
level of education, AB-related knowledge and the 
appreciation of the role of ABs in healthcare, 
which is line with other reports available in the 
literature [26,27]. 
The methodology and instrument used for this 
survey was based and adapted from the Euroba-
rometer survey on AMR by the European Com-
mission, one of the two most important interna-
tional studies, the Special Eurobarometer reports 
(Flash EBM 444 [28] in 2016, EBM 445 [23] in 2016 
and EBM 478 in 2018 [39], respectively) commis-
sioned by the European Union, and the ‘Antibiotic 
Resistance: Multi-country awareness survey’ for 
non-EU countries, performed by the WHO [30]. 
The highlights of the abovementioned reports are 
summarized in Table 5, serving as a contrast to the 
results of the present study. The average number 
of correct answers in the study region (2.1) was in 
line with previous reports of the Hungarian na-
tional average (in the EBMs 338, 407 and 445), 
however, in the last EBM, both the European over-
all average and the national average of Hungary 
has increased (2.6 and 2.3, respectively) [21,23,28-
30].
Table 4 Patients’ att itudes towards antibiotics and preventative measures to avoid contracting infectious diseases
Statements
SD D U/DK
n (%)
A SA
Disagree
n (%)
Agree
n (%)
QA1 Antibiotics are medicines of special im-
portance. 5 (4.6%) 11 (10.2%) 11 (10.2%) 37 (34.3%) 44 (40.7%)
QA2 My knowledge regarding infectious 
diseases is appropriate. 3 (2.8%) 20 (18.5%) 15 (13.9%) 48 (44.4%) 22 (20.4%)
QA3 Personal hygiene and taking care of our-
selves have important roles in the prevention 
of infectious diseases. 
1 (0.9%) 0 (0%) 0 (0%) 26 (23.9%) 82 (75.2%)
QA4 Vaccines are an important means of 
preventing infectious diseases. 8 (7.4%) 6 (5.6%) 10 (9.3%) 31 (28.7%) 53 (49.1%)
QA5 The media devotes enough energy to dis-
seminate information on infectious diseases. 16 (15.0%) 26 (24.3%) 17 (15.9%) 29 (27.1%) 19 (17.8%)
SD: strongly disagree, D: disagree, U/DK: I don’t know/Unsure, A: agree, SA: strongly agree
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By the recommendations of the European Sur-
veillance of Antimicrobial Consumption Network 
(ESAC-Net), AB use in adults is only indicated in 
around 0-30% of cases in upper respiratory tract 
infections, acute tonsillitis, acute or chronic sinus-
itis, acute otitis media, acute bronchitis or bronchi-
olitis, while for acute cystitis and pneumonia, this 
ratio is 80-100% [10,11]. Several national and inter-
national studies have described gaps in public 
knowledge and issues regarding inappropriate AB 
use [11,18,31-34], characterized by their procure-
ment through non-prescription (predominantly 
Table 5 Summary of the fi ndings of the Special Eurobarometer reports (EU) and the ‘Antibiotic Resistance: Multi-country 
awareness survey’ (WHO) on AB-related knowledge and AB utilization [21,23,28-30].
Survey 
(Year)
Anti biotics 
in the last 12 
months (EU)
Source of 
antibiotics 
(EU)
Anti-
biotics 
taken 
for the 
fl u
Anti-
biotics 
taken to 
treat a 
cold
Average 
number 
of correct 
answers 
(EU)
Anti-
biotics 
are 
eff ective 
against 
the cold 
and fl u
Anti-
biotics 
are 
eff etive 
against 
viruses
All answers 
(n=4) are 
correct
EBM 407 
(2013)
[21]
35%; 
highest in 
Malta (48%), 
lowest in 
Sweden (24%)
From a medical 
prescription/
pharmacy: 
95%; 3% from 
a pharmacy, 
without a 
prescription; 
2% leftover 
from home
18% 13%
2.4 
(Hunga-
ry: 2.1); 
highest in 
Sweden 
(3.1), 
lowest in 
Romania 
(1.5)
41% 49% 22%
EBM 445 
(2016)
[23]
34%; 
highest in 
Malta (48%), 
lowest in 
Sweden (18%)
From a medical 
prescription/
pharmacy: 
93%; 4% from 
a pharmacy, 
without a 
prescription; 
3% leftover 
from home
16% 11%
2.5
(Hunga-
ry: 2.2); 
highest in 
Finland 
(3.1), 
lowest in 
Italy (1.9)
44% 43% 24%
EBM 478 
(2018)
[29]
32%; 
highest in Italy 
(47%), lowest 
in Sweden 
(20%)
From a medical 
prescription/
pharmacy: 
93%; 3% from 
a pharmacy, 
without a 
prescription; 
4% leftover 
from home
12% 8%
2.6 
(Hunga-
ry: 2.3); 
highest in 
Finland 
and 
Sweden 
(3.1), 
lowest in 
Romania 
and Latvia 
(2.1)
48% 28% 25%
WHO 
Multi-
country 
survey 
(2015)
[30]
35%; 
higher in 
lower income 
countries 
(42%), lower in 
higher income 
countries 
(29%)
From a medical 
prescription/
pharmacy: 
93%; 2% from 
a pharmacy, 
without a 
prescription; 
2% leftover 
from home; 3% 
from a friend or 
family member, 
1% from the 
Internet
- - - 64% - -
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from pharmacies) and non-medical (leftover 
drugs, drugs from family members or friends) 
sources. These studies have all highlighted the 
role of self-medication of antibiotics as a minor 
(0.5-8%), but still signifi cant portion of AB con-
sumption. In addition, the ignorance (risk-taking 
behaviour) or lack of understanding towards in 
ineff ectiveness of ABs against viral infections (and 
the common cold) was also identifi ed in a plethora 
of publications: many people identify all disease-
causing pathogens as “germs”, not distinguishing 
their biological characteristics and the subsequent 
therapeutic approach needed to treat them 
[11,18,31-34]. 
Educational campaigns and behavioural AMR 
strategies are essential to address both the knowl-
edge-based and social aspects of inappropriate AB 
use in the public, including the lowering of expec-
tations for AB prescriptions, and the highlighting 
of the dangers associated with AMR [35]. On the 
other hand, healthcare professionals’ responsibili-
ty on the matt er also has to be highlighted: as the 
doctor-patient and pharmacist-patient relation-
ship is unbalanced (from the standpoint of medi-
cal information), patients will adhere to the advice 
received (also highlighted by the results of this 
study) and feed off  of the inappropriate behaviors 
and att itudes of the respective healthcare profes-
sionals [17,36,37]. Thus, it may be concluded that 
without structural changes in the healthcare infra-
structure of a relevant country, true change cannot 
be att ained [38]. 
Some limitations of this study must be acknowl-
edged (which were also present in the standard-
ized Eurobarometer instrument): i) some of the 
questions rely on the respondents’ memory, 
which may lead to discrepancies or bias; ii) the 
principal assumption of the study is that the 
knowledge level and att itude of patients will in-
defi nitely determine their practices towards ABs 
and the practices of the respondents were not 
measured directly; iii) the presence of social desir-
ability bias in some of the questions; iv) geograph-
ical limitations (the study may only represent the 
patients of the Szeged District).
5. Conclusions
As the number of available antibiotics is dwin-
dling, one of the most important steps to preserve 
the effi  cacy of existing drugs is the use of educa-
tional campaigns in an att empt to augment the 
health behaviour of patients. Our paper aimed at 
the assessing and understanding of AMR-related 
general population behaviour in the Szeged Dis-
trict of Hungary, in a descriptive antibiotic-related 
questionnaire, based on the methodology of the 
Special Eurobarometer reports of the European 
Commission. As a highlight to our study, higher 
education levels were associated with bett er knowl-
edge and att itudes, in addition, the majority of re-
spondents were not aware of the diff erences be-
tween bacterial and viral infections and their treat-
ment. This study has built on existing research and 
generated data which may be used for the design-
ing and implementation of awareness campaigns, 
based on the needs of the local community. 
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Abstract
Introduction: Although analgesic and nonsteroidal anti-infl ammatory drugs (NSAIDs) are usually used to treat a diversity of ill-
nesses, their administration is linked with acute kidney injury and gastrointestinal side eff ects. The research of new biomolecules and 
natural products is still needed such as medicinal plants.
Aims: The present research was aimed to investigate, for the fi rst time, the anti-infl ammatory and anti-nociceptive eff ects of spearmint 
essential oil (SEO) in mouse models of acute infl ammation and pain.
Materials and Method: Chemical analysis of SEO was done by gas chromatography. The anti-infl ammatory activity was tested using 
two models of acute infl ammation namely carrageenan-induced paw edema and xylene-induced ear edema. Histological examination 
of both non-infl amed and infl amed tissues was evaluated. The anti-nociceptive activity was tested using the pain model induced by 
acetic acid.
Results: The main constituent of the SEO was found to be carvone (52.60%). The SEO exhibited a promising anti-infl ammatory eff ect 
as demonstrated by statistically signifi cant (p<0.05) inhibition of paw volume by 77.24% at the dose of 20 μL/kg and 65.87% at the 
dose of 200 μL/kg. Furthermore, topical administration of the SEO inhibited xylene-induced ear edema in comparison with the control 
group (p<0.05). The higher dose (200 μL /kg) signifi cantly (p<0.001) reduced xylene-induced ear edema which was similar to that 
observed with positive control (ketoprofen). The pathological analysis of the paws and ears revealed that SEO was capable of reducing 
cellular infi ltration and subcutaneous edema. Else, the SEO produced signifi cant anti-nociceptive activity (p<0.001) at higher dose by 
inhibiting spontaneous nociception.
Conclusion: These results support the use of SEO in the development of pharmaceuticals for the management of infl ammation and 
pain.
Keywords: Spearmint essential oil; Anti-infl ammatory eff ect; Carvone; Histological analysis; anti-nociceptive activity.
Abbreviations: ANOVA = Analysis of variance; COX-2 = Cyclooxygenase-2; EO = Essential oil; GC-MS = Gas Chromatog-
raphy-Mass Spectrometry; H&E = Hematoxylin-Eosin; IL= Interleukin; iNOS = Nitric Oxide Synthase; INF-γ = Interferon; 
IC50 = Median inhibitory concentration; LPS = Lipo-polysaccharide ; LTB4 = Leukotriene B4 ; NIH = National Institute of 
Health; NIST = National Standard Institute Technology; NSAIDs = Nonsteroidal Anti-Infl ammatory Drugs; NV = Neovas-
cularization; p.o. = per os; PBS = Phosphate-buff ered saline; PGE2 = Prostaglandin E2; SEO = Spearmint essential oil; PMN = 
Polymorphonuclear cells’; RT = Retention Times; SD = Standard Deviation; TNF = Tumor Necrosis Factor.
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1. Introduction
Infl ammation is an imperative biological reaction 
which happens in answer to a varied range of in-
jurious agents such as physical trauma, bacterial 
infection, chemicals or any additional physical 
phenomenon. Infl ammation is the complex state 
of hyperemia from blood vessels with resulting 
warmness, redness, swelling and discomfort [1]. 
Immune reaction is important for the body to 
eliminate and remove hazardous pathogens by 
way of an acute infl ammation [2]. Infl ammation 
usually implicates edema and pain at the location 
of injury or wound due to discharge of many pro-
infl ammatory chemical mediators along with the 
escape of liquid from the vascular tissues due to 
increase in the penetrability of the vessel barriers, 
tissue damage, infi ltration and migration of in-
fl ammatory cells and healing [3]. All kinds of 
pain, whether it is chronic or acute, initiate from 
infl ammation. During infl ammation, several pro-
infl ammatory chemical factors such as interferon 
(INF-γ), tumor necrosis factor (TNF), cyclooxygen-
ase-2 (COX-2), interleukins (IL-6 and IL-12), and 
inducible nitric oxide synthase (iNOS) are synthe-
tized and secreted. The receptors involved in in-
fl ammation are similarly stimulated in pain [4].
Non-steroidal anti-infl ammatory drugs 
(NSAIDs), such as diclofenac sodium, are among 
the most frequently recommended medications 
due to their regular effi  ciency in the management 
and treatment of infl ammation, pain and rheu-
matic complaints [5]. Nevertheless, their adminis-
tration is linked with undesirable eff ects at the 
level of digestive area, ranging from gastrointesti-
nal erosions and severe peptic ulcers to more 
grave problems, such as over bleeding or full 
damage of epithelial membrane. Other NSAIDs 
adverse reactions comprise hepatic, renal and car-
diovascular undesirable eff ects which are correlat-
ed to the agent as well as the frequency and peri-
od of treatment [6]. Then, to overcome the toxicity 
of NSAIDs, the investigation of new and promis-
ing molecules is still required and the natural 
products such as aromatic and medicinal plants 
could lead in the development of new anti-infl am-
matory and analgesic drugs with fewer side ef-
fects.
Numerous species of Mentha genus are used in 
phytotherapy as fl avor agents and as herbal medi-
cines for several human therapeutic administra-
tions [7]. Spearmint (Mentha spicata L.) is generally 
cultivated in diff erent regions worldwide to com-
mercially produce its aromatic or essential oil 
(EO) [8]. Spearmint has several therapeutic prop-
erties and health benefi ts and is used in phyto-
medicine as antifungal, diuretic, carminative and 
antioxidant agents, and for management of colds 
and fl u, hemorrhoids, respiratory tract problems 
and stomach ache. Interestingly, spearmint essen-
tial oils (SEOs) were recognized as rich in oxygen-
ated monoterpenes and were found to have anti-
microbial activity [9,10]. It is also a nontoxic and 
real therapeutic choice for the cure of chemothera-
py-induced emesis and nausea in patients [11].
Although several studies have been reported on 
the chemical composition, antimicrobial and anti-
oxidant activities of spearmint essential oil in vitro 
[7-10], however only few investigations report its 
pharmacological eff ects in vivo. Based on the 
above refl ections, the present research reports, for 
the fi rst time, the chemical composition of essen-
tial oil obtained from the leaves and stems 
of spearmint grown in Algeria as well as the in 
vivo anti-infl ammatory and anti-nociceptive ef-
fects.
2. Material and methods
2.1. Materials
2.1.1. Extraction of Spearmint essential oil
Spearmint (Mentha spicata L.) leaves and stems 
were collected on june 2016 in the Cherchell re-
gion (Tipaza, Algeria). This area is located in the 
eastern region of Algiers (coordinates 35°52’34’’N 
latitude and 0°17’20’’W longitude). SEO was ex-
tracted from the aerial part of spearmint with and 
alembic steam distillation (Extral-Bio company, 
Chiff a, Blida, Algeria). The whole quantity of fresh 
plant used was 450 kg, and it was loaded in the 
still and stacked in layers to allow appropriate de-
livery of the steam. The process consists of pass-
ing water vapor at a high-pressure through an 
alembic (tank) fi lled with spearmint. The SEO was 
stored in a sealed vial, at 4 °C, before use.
2.1.2. Chemicals and drugs
The following drugs and chemicals were used: di-
methyl sulfoxide (DMSO), sodium diclofenac, car-
rageenan, xylene, tween 80, isosaline (0.85%) and 
phosphate-buff ered saline (PBS) solutions were 
purchased from Sigma Chemical Co. (St. Louis, 
MO, USA). Ketum gel® 2.5% (Ketoprofene 60 g, 
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Laboratoire Menarini, Barcelona, Spain), Spasfon® 
80 mg (Phloroglucinol, Teva Sante, Paris, France), 
Ketamile® (Ketamine chlorydrate, El Kendi Phar-
maceuticals, Algiers, Algeria) and Votrex® 50 mg 
(sodium diclofenac, Hikma Pharmaceuticals, Jor-
dan) were also used.
2.1.3. Animals
Swiss NMRI male mice (25.28±1.75 g) were got 
from the animal breeding of SAIDAL pharmaceu-
tical company (Algiers, Algeria). The mice were 
used in agreement with the guiding principles in 
the care and use of animals agreed by the Council 
of the American Physiologic Society. The mice 
were permitt ed free access to water and food un-
der conditions of optimum light (12 hours light-
dark cycle) with the room temperature maintained 
at 25±3 °C and relative humidity of 45-60%. In an-
ti-infl ammatory and analgesic assays, mice were 
arbitrarily separated into fi ve groups: control, 
NSAID, and SEO (200, 20, and 2 μL/kg) groups. All 
experiments were done between 9:00 a.m. and 3:00 
p.m. All labors were done in order to diminish an-
imal suff ering.
2.2. Methods
2.2.1. Determination of the chemical composition of 
spearmint essential oil
The chromatographic analysis of the SEO was 
done using a Shimadzu gas chromatograph (Shi-
madzu Corporation, Kyoto, Japan), coupled with a 
Shimadzu mass spectrometer detector QP-5050A. 
The GC-MS system was equipped with a Tracsil 
Meta.X5 column, 95% polydimethylsiloxane and 
5% polydiphenylsiloxane (Teknokroma S. Coop. C. 
Ltd., Barcelona, Spain; 60 m × 0.25 mm × 0.25 μm 
fi lm thickness). Analysis was done using He as 
carrier gas at a column fl ow of 0.3 mL/min with a 
split ratio of 1:200. The oven temperature program 
was as follow: (a) 80 °C, 0 min; (b) rate of 4 °C/min 
from 80 to 210 °C and hold for 1 min; (c) rate of 25 
°C/min from 210 to 300 °C and hold for 8 min. The 
temperatures of the injector and detector were 230 
and 300 °C, respectively. All chemical compounds 
were detected and identifi ed using two diff erent 
techniques: (1) mass spectra (NIST05 spectral li-
brary collection), and (2) comparison of their ex-
perimental retention indices (RI) with those of 
the literature. Only fully identifi ed compounds 
are reported in this study.
2.2.2. In vivo anti-infl ammatory activity
2.2.2.1. Carrageenan-induced paw edema in mice
Carrageenan-induced paw edema in mice is a 
well-established technique of acute infl ammation 
for evaluation of anti-infl ammatory molecules. 
This method was similar to that reported by 
Mogosan et al. [12]. Mice (six weeks old) weighing 
about 24–27 g were randomly divided into fi ve 
groups of six animals; including a control group 
(vehicle, isosaline NaCl 0.9%); SEO groups (2, 20 
and 200 μL/kg), and NSAIDs group (diclofenac so-
dium, 50 mg/kg), as the standard drug. The desig-
nated groups were orally treated with vehicle, 
SEO, or NSAIDs 40 minutes before λ-carrageenan 
injection. For induction of infl ammation, the mice 
received an injection of 100 μL of 1% (w/v) suspen-
sion of λ-carrageenan in saline, into the mouse›s 
plantar side of the left hind paw after 40 min of 
the oral administration of the sample. The animals 
were sacrifi ced 4 hours later. The diff erence in 
weight between right untreated and left treated 
hind paws was calculated and results are ex-
pressed as the increase in paw weight (mg). The 
percentage inhibition of the infl ammatory re-
sponse was calculated by comparison to the nega-
tive control and SEO or NSAIDS groups by using 
this formula:
% Inhibition of edema = (Ct-C0)Control - (Ct-C0)Treated(Ct-C0)Control)( ) x 100
Where (Ct−C0) control is the diff erence in the 
weight of paw at 4 hours in control animal, and 
(Ct−C0) treated is the diff erence in the weight of 
paw at 4 hours in animal treated either with the 
standard drug or SEO.
At the end of the assay, the mice were eutha-
nized by diethyl ether and the infl amed paws 
were removed and fi xed in 10% formaldehyde so-
lution for histological analysis and examination.
2.2.2.2. Histological examination of mouse paw tissue
To further confi rm the infl ammatory changes in 
paw of animals after injection of carrageenan, the 
mice were sacrifi ced 4 h after the generation of in-
fl ammation. The sub-plantar paw tissue samples 
were then removed, fi xed in 10% neutralized for-
malin for 24 h, dehydrated with alcohol (ethanol), 
surrounded in paraffi  n wax (56 °C) and cut into 5 
μm thick sections. Successive sections were 
stained with haematoxylin and eosin (H&E) stain 
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to establish the degree of edema and infl amma-
tion [13]. The stained sections were examined un-
der a light microscope and the histological modifi -
cations were registered with the assistance of a 
pathologist. The severity of paw tissue infl amma-
tion was evaluated by two independent observers 
blinded to the method protocol.
2.2.2.3. Xylene-induced mice ear edema
Topical infl ammation was done using ear edema 
model according to the method of Boukhatem et 
al. [13]. Adult Swiss albino mice were arbitrarily 
divided into fi ve groups, each containing six mice. 
The acute infl ammation was made on the posteri-
or and anterior surfaces of the right ear by the top-
ical application of 20 μL/ear of xylene. The left ear 
(untreated) was considered as a control. To deter-
mine the topical anti-infl ammatory eff ect, SEO di-
luted in almond oil was applied topically at diff er-
ent doses (200, 20 and 2 μL/kg) 40 minutes before 
the xylene application. Another group was treated 
only with vehicle (almond oil) and was considered 
as a control. Ketoprofen (NSAIDs) was used as a 
reference drug. Four hours after the application of 
xylene, the animals were sacrifi ed and two ear 
punches (6 mm diameter) were taken from from 
both untreated (left) and treated (right) ears and 
weighed. The weight diff erence between the right 
and left ear disks of the same mice was assessed 
as the intensity of edema. The anti-infl ammatory 
eff ect was estimated and expressed as a percent-
age reduction of edema in treated mice compared 
with the control and calculated using the follow-
ing formula: 
% Inhibition of topical edema = 6Wt6Wc( ) x 1001 -
where ΔWt is the change in weight of ear tissue in 
the treated mice, and ΔWc the change in weight of 
ear tissue in the control mice (vehicle).
2.2.2.4. Histological examination of mouse ear tissue
The subsequent infl ammatory response was as-
sessed and monitored by estimation of edema for-
mation and by microscopic observation. For the his-
tological study of cutaneous infl ammation, two 
samples of the swollen ears from the control and 
the SEO treated groups were removed and fi xed in 
10% formaldehyde for one week. Then, the fi xed ear 
tissues were implanted in paraffi  n, routinely pro-
cessed and sectioned at 5 μm using a microtome 
(LEICA RM, Nussloch, Germany). The slices were 
mounted on the glass slides, stained with H&E and 
lastly observed and examined by a pathologist in a 
blinded way. The ear tissues were observed with a 
light microscope (Olympus CX41) and graded as 
minor (+), modest (++), or severe (+++) for infl amma-
tion phase. Infi ltration and polymorphonuclear 
(PMN) cells’ accumulations and infi ltration were 
also reported [13]. The histological examination was 
carried out in the laboratory of histopathology, Hos-
pital of Kolea (Tipaza city, Algeria).
2.2.3. In vivo anti-nociceptive activity of SEO using 
acetic acid-induced writhing test
The anti-nociceptive activity of SEO was investi-
gated using the writhing assay (abdominal con-
striction test), according to the method of Mogo-
san et al. [12]. A total number of 30 male mice 
were divided into fi ve groups. Briefl y, mice were 
treated orally with phloroglucinol (Spasfon 80® 
mg/kg, i.p.) which is considered as a standard an-
algesic drug. Also, SEO and vehicle (isosaline, 
NaCl 0.9%) were administrated orally 30 min. Af-
ter that, intra-peritoneal injection of acetic acid 
(0.6%) was done for the induction of abdominal 
contractions. The number of abdominal contrac-
tions or writhes were counted for each group of 
mice starting from one minute after the injection 
of acetic acid up to 10 minutes and expressed as 
percent protection. The anti-nociceptive activity 
was estimated as the percentage of inhibition of 
abdominal contractions between the control and 
the treated groups (SEO or standard drug) using 
the following formula:
Nc – Nt
Nc( )x 100Protection (%) =
Where Nc is number of writhing in control, and Nt 
is the number of writhing in test mice.
2.2.4. Statistical analysis
Data obtained in our research was presented as 
mean ± SD where each value represents a mini-
mum of 6 mice. One way analysis of variance 
(ANOVA) was done to evaluate the variability 
among groups. Signifi cant diff erences among 
groups were calculated using Tukey’s multiple 
comparison tests in which the results were com-
pared with that of control group. The results were 
considered statistically signifi cant at p<0.05. XL-
STAT software 2014 for Windows (Addinsoft, Par-
is, France) was used for all statistical analysis.
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3. Results and discussion
3.1. Chemical composition of spearmint essential oil 
using GC-MS analysis
The EO was extracted by steam distillation from 
the dried aerial parts of spearmint from the Cher-
chell region (Tipaza, Algeria), and was analyzed 
by GC-MS (Figure 1 shows a representative chro-
matogram). The SEO showed a diverse composi-
tion with 19 constituents reported in Table I The 
most abundant chemical components were oxy-
genated monoterpenes 64.7%, followed by mono-
terpene hydrocarbons (28.84%), and sesquiterpene 
hydrocarbons (6.46%). The main constituents were 
carvone (52.60%) and limonene (24.99%), followed 
by 1.8-cineole (7.22%) and trans-caryophyllene 
(3.38%). Other chemical compounds were detected 
but were less than 3%.
The EO of this Algerian variety of mint can be as-
cribed to the carvone/limonene chemotype. Actual-
ly, there is great variation in the chemical composi-
tion of spearmint, cultivated as well as endemic or 
wild, around the world. Remarkably, our SEO 
seems to be richer with some main compounds 
such as eucalyptol (1.8-cineole) and oxygenated 
monoterpenes. A review of the literature accessible 
on this theme shows that several articles have pre-
viously been published on SEOs chemical composi-
tion [10,11]. In addition, our fi ndings about most 
major chemical constituents of SEO collected from 
the center part of Algeria are in agreement with 
previous reports [8,9]. Govindarajan et al. [14] stud-
ied the chemical composition of SEO obtained from 
Tamilnadu (India) and reported carvone (48.60) 
and limonene (11.30%) as the dominant com-
pounds. Padalia et al. [15] reported the chemical 
composition of 16 cultivars of Chinese Mentha spe-
cies and revealed that carvone (51.3%–65.1%) and 
limonene (15.1%–25.2%) are the principal com-
pounds in fi ve cultivars of spearmint. In contradic-
tion with our data, Telci et al. [16] studied chemical 
composition and antimicrobial eff ect of SEO and 
demonstrated that piperitone and pulegone were 
the main components. Else, El-Sayed et al. [17] con-
fi rmed that menthone (32.43%) and eucalyptol 
(18.79%) were the dominant constituents of the 
Egyptian SEO. Further, a linalool-rich chemotype 
(82.8%) was described from Turkey [18].
Usually, the observed changes in chemical com-
position of SEO, when compared with earlier re-
ports, could be linked to diff erent abiotic or biotic 
factors comprising several extraction methods, cli-
mate and seasonal variations, geographical condi-
tions, relative humidity, agronomic conditions 
(harvesting time, crop density, organic fertilizers), 
genotype, stage of the plant growth and process-
ing of plant materials before distillation of the 
SEO [19].Figure 1 Chromatogram of SEO analysed with GC-MS.
Table I Chemical composition of Algerian Mentha spicata 
(L.) essential oil using GC-MS.
RT (min) Name %
8.855 α-Pinene 0.66
9.742 β-Pinene 1.97
10.132 β-Myrcene 0.77
10.853 Limonene 24.99
10.899 1.8-Cineole 7.22
11.178 β-Ocimene 0.10
11.324 γ-Terpinene 0.35
11.487 cis-Terpineol 0.16
13.253 Terpineol-4 1.22
13.562 cis-Dihydrocarvone 1.06
13.655 Dihydrocarveol 0.88
14.187 Pulegone 0.38
14.442 Carvone 52.60
15.392 Dihydrocarvyl acetate 0.82
15.858 cis-Carvyl acetate 0.36
16.154 β-Bourbonene 1.87
16.234 β-Elemene 0.96
16.610 trans-Caryophyllene 3.38
17.022 α-Humulene 0.25
Oxygenated Monoterpenes 64.7
Monoterene Hydrocarbons 28.84
Sesquiterpene Hydrocarbons 6.46
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3.2. In vivo anti-infl ammatory activity
3.2.1. In vivo anti-infl ammatory activity using 
carrageenan-induced paw edema test
The anti-infl ammatory eff ect of medicinal herbs 
has been confi rmed and few others refuted. 
Therefore the present research is carried out with 
a purpose to screen the eff ectiveness of anti-in-
fl ammatory potential of SEO in experimental ani-
mals. The acute infl ammation was experimentally 
made by carrageenan to evaluate the anti-infl am-
matory property of SEO in mice. Subcutaneous in-
jection of carrageenan produced an increase in 
animal paw weight due to edema, thus demon-
strating acute infl ammation.
As shown in Table II, SEO showed an interesting 
anti-infl ammatory potential. At 4 hours after oral 
administration of SEO, the weight of treated left 
hind paw was similar for 200 μL/kg and 20 μL/kg 
(3.7±6.3 mg and 02.5±3.48 mg, respectively) with 
edema inhibition values of 65.87% and 77.24%. This 
level of edema inhibition was similar to the level 
detected using 50 mg/kg of the standard reference 
drug (85.32%). Our fi ndings revealed that treat-
ment with SEO was eff ective in decreasing the ede-
ma induced by carrageenan. However, the drug 
used as a reference (sodium diclofenac) was more 
eff ective in preventing these eff ects.
The carrageenan-induced paw edema assay is 
the most commonly used test to determine new 
anti-infl ammatory molecules or drugs. This model 
is greatly reproducible and has been well recog-
nized as an eff ective technique to investigate pro-
infl ammatory cytokine generation and mediators 
(serotonin, histamine, prostaglandins and brady-
kinin) in the paw tissue in infl ammatory situa-
tions [12,20].
Our investigation presents a primary research 
and additional studies are needed to explain the 
eff ect and mechanism of action of the SEO compo-
nents. Several studies reported that the anti-in-
fl ammatory activities obtained with SEO might be 
related to some anti-infl ammatory molecules such 
as oxygenated monoterpenes (carvone and euca-
lyptol) [20,21]. In fact, D-carvone inhibited the ani-
mal hind paw edema induced by various phlogis-
tics (histamine, carrageenin, dextran and bradyki-
nin) in a dose-dependent manner [20].
In addition, it has been reported that mint oil 
also prevents the infl ammatory consequences of 
Lipo-polysaccharide (LPS), together with inhibi-
tion of prostaglandin E2 (PGE2), interleukin-1 (IL-
1) and leukotriene B4 (LTB4) production by LPS-
stimulated human monocytes [22,23].
3.2.2. Histological examination of the mice paws after 
injection of carrageenan
To confi rm the anti-infl ammatory eff ect of SEO 
histologically, paw biopsies were harvested 4 h af-
ter carrageenan had been injected. Paw tissues 
from all the groups of animal were examined by 
H&E staining. The control groups not induced by 
infl ammation showed normal tissue (Figure 2A) 
with no infl ammation, tissue destruction or swell-
ing phenomenon in the paws of normal mice. On 
the other hand, the animal injected with carra-
geenan (Figure 2C) showed a strong edema and in-
fl amed cavities in the paw tissue, characterized by 
congestion of blood vessels, dermal and epithelial 
tissue with an important number of infi ltrated in-
fl ammatory cells detected in the paw tissue. The 
cell types were mostly neutrophils, which describe 
acute infl ammation.
As for the positive (Figure 2B) and SEO groups 
(Figure 2D, E and F), edematous condition was 
clearly decreased by treatment with NSAID (di-
clofenac sodium, 50 mg/kg) and SEO (2, 20, and 
Table II In vivo Eff ects of the spearmint EO (2, 20 and 20 μL/kg) and diclofenac sodium (50 mg/kg) on carrageenan-induced 
paw edema in mice.
Treatment Weight (mean, mg) ± SD
Left paw Right paw Edema weight # % Inhibition of edema
Negative control (Vehicle) 140.2±18.72 129.3±11.68 10.9±15.19 B /
Positive control (NSAID) 132.4±8.99 130.8±10.00 1.6±3.21 A 85.32
SEO 200 134.1±13.38 130.4±17.54 3.7±6.30 AB 65.87
SEO 20 139.7±12.39 137.2±15.07 2.5±3.48 AB 77.24
SEO 2 140.1±12.08 132.9±18.34 7.2±14.03 AB 33.57
Groups of mice (n = 6/group) were pretreated with vehicle (NaCl, 0.9%), NSAID: non-steroidal anti-infl ammatory drugs (Sodium 
diclofenac, 50 mg/kg, p.o.). SEO: Spearmint essential oil at doses of 2, 20, and 200 μL/kg (p.o.) # Means within the same column 
followed by the same capital lett er are not signifi cantly diff erent (p>0.05) according to ANOVA one way analysis followed by 
Tukey’s post hoc multiple comparison test.
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200 μL/kg) as well as a decrease in the 
infi ltration of infl ammatory cells. At 
higher dose of SEO, treated animals 
showed a bett er eff ect in decreasing of 
neutrophils as compared with stan-
dard drug (Figure 2F vs 2C).
 Our fi ndings clearly establish the 
property of SEO within the target tis-
sue, giving additional confi rmation 
that SEO reduces carrageenan-in-
duced paw edema. Mogosan et al. [12] 
stated that the treatment of SEO inhib-
ited the edema and decreases the cel-
lular infi ltrates probably by decreas-
ing the infl ammatory chemical media-
tors.
The histopathological fi ndings also 
substantiate with the paw edema 
analyses. Histopathological examina-
tions indicated that edema formation 
and, infl ammatory cell infi ltration 
were obviously suppressed in the ani-
mal treated with the SEO. These data 
support the results obtained from the 
paw edema test and confi rm the anti-
infl ammatory action of SEO against 
acute infl ammation.
The use of current NSAIDs is fre-
quently associated with severe and 
diff erent side eff ects. Hence alterna-
tive therapeutic molecules are re-
quired. Few studies have been initiat-
ed around the world into researching, 
evaluating and analyzing the local 
medicinal plants with anti-edematous 
values. In spite of the medicinal po-
tential of SEO, its eff ect on infl amma-
tion has not been previously reported 
in detail. Therefore, in the present 
study, we screened and confi rmed for 
the fi rst time the anti-infl ammatory ef-
fi cacy of SEO against carrageenan in-
duced paw edema followed by histo-
logical analysis.
3.2.3. In vivo anti-infl ammatory activity 
using xylene-induced ear edema assay
The anti-infl ammatory eff ect of SEO 
was further assessed by the inhibition 
of xylene-induced ear edema. As 
shown in Table III, topical application 
of xylene in the control group caused 
A1 A2
Right paw (control) (Gx10) = Edema (-); infl ammatory cell infi ltration (-), 
infl ammation phase (-).
B C
Positive control treatment 
(sodium diclofenac) (Gx40)
Edema (±); infl ammatory cell 
infi ltration (+), infl ammation phase 
(±).
Negative control = λ-carrageenan 
group (Gx40)
Edema (++); infl ammation phase 
(+++); infl ammatory cell infi ltration 
(+++) in epidermal and dermal 
layers, muscle and cartilage.
D1 D2
SEO treatment (2 μL/Kg) (D1 x10; D2 x10)
Edema (±); infl ammatory cell infi ltration (+), infl ammation phase (±).
E1 E2
SEO treatment (20 μL/Kg) (E1 x10; E2 x40)
Edema (±); infl ammatory cell infi ltration (+), infl ammation phase (±).
F1  F2
SEO treatment (200 μL/Kg) (F1 x10; F2 x40)
Edema (±); infl ammatory cell infi ltration (+), infl ammation phase (±).
Ke: keratin; Ep = epidermal layer; SC = subcutaneous layer; Bt = bone tissue; Mu = muscle fi bers; Gs = sebaceous 
gland; PCI = polymorphonuclear cells infi ltration; MC = mononuclear cells; Ed: edema.
Figure 2 Histopathological examinations on λ-carrageenan-induced paw 
tissue swelling, edema and neutrophil infi ltration. Light photomicrographs 
of the H&E stained paw tissue in the (A) control group (right paw), (B) 
NSAIDs group, (C) λ-carrageenan group, (D) SEO (2 μL/kg), (E) SEO 
(20 μL/kg) and (F) SEO (200 μL/kg) groups. Paws were harvested 4 h after 
injection of carrageenan and subjected to histochemical staining.
Acta-2001.indb   21 6/8/20   4:09 PM
22 Acta Pharmaceutica Hungarica DOI:  10.33892/aph.2020.90.15-26
a marked increase in the weight of the ears. How-
ever, the topical administration of the SEO (200, 20 
and 2 μL/kg), 40 minutes before xylene applica-
tion, decreased the development of ear edema. 
The inhibitory eff ect of the oil was similar to the 
inhibition caused by ketoprofen (Figure 3). Treat-
ment of the mice with a high dose of 
SEO suppressed xylene-induced ear 
edema, reducing swelling by 94.44% 
(p<0.001). The data indicate that SEO 
possesses inhibitory eff ects against 
acute infl ammation.
Our fi ndings revealed that SEO can 
markedly prevent the formation of 
xylene-induced ear edema. Mice ear 
edema may comprise the release of 
pro-infl ammatory chemical media-
tors, increasing vascular permeabili-
ty, leukocytes infi ltration, plasma 
leakage and the production of cyto-
kines such as interleukin 1β, tumor 
necrosis factor alpha (TNF α) [24]. 
SEO may produce the anti-infl amma-
tory action by infl uencing the actions 
of the above mediators [22,25].
NSAIDs are usually among the 
most used drugs in the treatment of 
infl ammation. Unfortunately, the use 
of NSAIDs is restricted by several adverse eff ects 
and about 20% of patients will develop gastric ul-
cer [12]. Our study demonstrated that SEO 
showed similar eff ects with NSAIDs on the two 
models of infl ammation (carrageenan and xy-
lene).
 Table III Eff ects of the SEO (2, 20 and 200 μL/kg) and Ketoprofen (5 mg/ear) on xylene-induced ear edema in mice.
Treatment Weight (mean, mg) ± SD
Right ear Left ear Edema weight # % inhibition of edema
Negative control (Vehicle) 9±0.44 12.6±1.34 3.6±1.14 B -
Positive control (NSAID) 7.4±1.51 7.8±1.09 0.4±1.14 A 88.88
SEO 200 μL/kg 8±0.83 8.2±0.83 0.2±0.54 A 94.44
SEO 20 μL/kg 8±0.54 8.4±0.54 0.4±0.44 A 88.89
SEO 2 μL/kg 7.4±0.89 8.8±0.83 1.4±1.14 A 61.11
Groups of mice (n = 6/group) were pretreated with vehicle, NSAID: non-steroidal anti-infl ammatory drug (Ketoprofen 2.5%). 
SEO: Spearmint essential oil at doses of 2, 20, and 200 μL/kg (topically). # Means within the same column followed by the same 
capital lett er are not signifi cantly diff erent (p>0.05) according to ANOVA one way analysis followed by Tukey’s post hoc multiple 
comparison test.
Table IV Study of anti-nociceptive activity of SEO by acetic acid-induced writhing test
Treatment Number of writhing(Mean ± SD) #
Inhibition
(%)
Negative control (acetic acid) 77.8 ± 5.40 B -
Positive control (Phloroglucinol) 55.6 ± 9.09 A 28.53 ***
SEO 200 μL/kg 59.4 ± 5.89 A 23.65 **
SEO 20 μL/kg 65.2 ± 3.96 A 16.19 *
SEO 2 μL/kg 65.24 ± 3.96 AB 16.14 ns
SEO: mice treated with spearmint essential oil at diff erent doses (2, 20, and 200 μL/kg, p.o). Values are expressed as mean ± SD 
(n = 6, per group); * p<0.05; ** p<0.01; *** p<0.001. # Means within the same column followed by the same capital lett er are not 
signifi cantly diff erent (p>0.05) according to ANOVA one way analysis followed by Tukey’s post hoc multiple comparison test.
Figure 3 Topical anti-infl ammatory eff ect of SEO in xylene-induced ear edema. 
Vehicle: control group (mice treated with almond oil topical application); SEO: mice treated with 
spearmint essential oil topically at diff erent doses (2, 20, and 200 μL/kg) per ear; NSAID: mice 
treated with non-steroidal anti-infl ammatory drugs (ketoprofen 2.5%). Values represent the mean 
± SEM. *** signifi cant diff erence (p<0.001) according to ANOVA one-way analysis followed by 
Tukey’s post hoc multiple comparison tests.
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3.2.4. Examining the mouse ear tissue 
histology
Anti-infl ammatory eff ect of SEO on 
the carrageenan test led us to deter-
mine this eff ect in another neurogenic 
infl ammatory assay (xylene-induced 
ear edema). We investigated H&E 
stained ear sections from xylene-in-
duced ear edema (Figure 4).  By histo-
logical comparison, topical application 
of SEO decreased paw thickness and 
associated pathological indicators 
(Figure 4D, E and F) comparable to the 
positive control (ketoprofen gel) 
(Figure 4C).
The ear edema model induced by 
xylene has certain advantages in the 
determination of NSAIDs and has bet-
ter predictive values in the screening 
of anti-infl ammatory new molecules 
[23]. Xylene-induced swelling is fol-
lowed by innate immunity reaction of 
the skin, a cytotoxicity response of ac-
tivated T cells followed by the migra-
tion of polymorphonuclear leucocytes 
which enhance infl ammation and 
swelling of the ear. The pathological 
examination of infl amed tissues (paws 
and ears) showed that SEO inhibited 
infi ltration of polymorphonuclear leu-
cocytes into the site of infl ammation. 
Therefore, another option is that SEO 
exerts its anti-edematous action partly 
through the inhibition of polymor-
phonuclear cell infi ltration [22,23,25]. 
In addition, the chemical composition 
of SEO revealed the presence of high 
quantity of oxygenated terpene com-
pounds such as carvone, menthol and 
eucalyptol. Literature review showed 
that the presence of these compounds 
in the SEO may be the main reason of 
its important anti-infl ammatory prop-
erty [21].
3.3. In vivo eff ect of SEO on acetic 
acid-induced writhing response
 
Acetic acid induced writhing experi-
ment was done to evaluate the periph-
eral analgesic property of SEO. It is 
well known that acetic acid in some 
A1 A2
Control (left ear) (x10)
Edema (-); infl ammatory cell infi ltration (-), infl ammation phase (-).
B1 B2
Negative control = λ-carrageenan group ((B1 x10; B2 x40)
Congestion of vessels and a substantial number of infi ltrated infl ammatory cells.
Edema (++); infl ammation phase (+++); infl ammatory cell infi ltration (+++) in epider-
mal and dermal layers, muscle and cartilage.
C
Positive control treatment (Ketoprofen 2.5%) (Gx10) =
Edema (-); infl ammatory cell infi ltration (-), infl ammation phase (-).
D1 D2
SEO treatment (2 μL/Kg) (D1 x10; D2 x40)
Edema (-); infl ammatory cell infi ltration (-), infl ammation phase (-).
E1 E2
SEO treatment (20 μL/Kg) (E1 x10; E2 x40)
Edema (-); infl ammatory cell infi ltration (-), infl ammation phase (-).
F1 F2
SEO treatment (200 μL/Kg) (F1 x10; F2 x40)
Edema (-); infl ammatory cell infi ltration (-), infl ammation phase (-).
Figure 4 Pathological examination of ear tissues after topical administration of xylene.
Histopathology sections of mice ear biopsies showing keratin, epidermal, dermal, muscle, and cartilage 
layers. Hematoxylin & Eosin stained sections were scored as mild (+), modest (++), and severe (+++) for 
edema and substantial infl ammatory polymorphonuclear cell infi ltration (PCI) in the dermis infl amma-
tion phase.
(A) Normal Ear; (B) Control: Topical Application of xylene (20 μL/ear) showed induced infl ammatory le-
sion with edema and infi ltration of polymorphonuclear leukocytes; (C) Ketoprofen decreased the indicated 
changes; Topical Application of the SEO at doses of 2 (D), 20 (E) and (F) 200 μL/kg after 4 h of topical 
xylene was able to decrease epidermis thickness, edema, and infi ltration of polymorphonuclear leukocytes.
Ke: keratin; Ep: epidermal layer; Bo: bone tissue; PCI: polymorphonuclear cells infi ltration; Ed: edema; 
Mu: muscle.
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way is responsible for secretion of endogenous 
mediators thereby stimulating the neurons re-
sponsible for pain perception, which are receptive 
to NSAIDs [26]. In this research, SEO showed a 
signifi cant in vivo analgesic eff ect using the acetic 
acid-induced writhing test. Intraperitoneal (i.p) in-
jection of acetic acid produced 77.8±5.40 writhes in 
the solvent control group (Table IV and Figure 5). 
The writhing response was signifi cantly de-
creased by pretreatment with 200 μL/kg of SEO 
(77.8±5.40; p<0.01). Standard group which received 
Spasfon (Phloroglucinol) showed 28.53%  (p<0.001) 
of inhibition in writhing movement.
The analgesic properties of mint species have 
been studied and demonstrated by several au-
thors [12,27]. In this study, we evaluated the anti-
nociceptive eff ect of SEO using the acetic-acid in-
duced pain model. The oral administration of 
SEO produced signifi cant inhibition of the acetic 
acid-induced abdominal writhing in dose depen-
dent manner in the mice, but the inhibition was 
similar to that produced by Phloroglucinol only 
at a higher dose (200 μL/kg). These data suggest 
that SEO may produce peripheral analgesic ac-
tivity by inhibiting the chemical mediators and/
or cytokines (histamine, serotonin, bradykinin, 
cytokines, and eicosanoids). These mediators 
stimulate an increase of vascular permeability as 
well as reduce the threshold of nociception and 
stimulate the nervous terminal of nociceptive fi -
bers [7,23]. The anti-infl ammatory and anti-noci-
ceptive activities of SEO may be related to the 
synergy interactions of its major or 
minor chemical components such as 
carvone, limonene and eucalyptol 
[28].
4. Conclusion
Our fi ndings clearly confi rmed that 
SEO has a potent peripheral analgesic 
activity and also demonstrated sys-
temic and local anti-infl ammatory 
properties in carrageenan and xylene 
models and these preliminary data 
could provide some credit for the po-
tential use of spearmint as a bioactive 
agent for the treatment-prevention of 
infl ammatory and painful condi-
tions. Additional cellular and molec-
ular assays will be done to investigate 
its real mechanisms of SEO including 
its active components such as car-
vone and limonene, alone or in combination, and 
to characterize the receptors involved in the anti-
nociceptive and anti-infl ammatory eff ects. A sys-
temic study is required to produce nutraceuticals 
drug from SEO for treating various health prob-
lem of human kind.
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Abstract
Drug administration through the nose off ers great possibilities which have been discovered in the past few decades. Besides the most 
known local eff ect, systemic and central nervous system eff ect is also available, the administration is non-painful and the degradation 
eff ect of the gastrointestinal tract can be avoided. Amongst the nasal formulations, powders have become more popular as their stability 
is favorable compared to the liquid formulations and a higher doses can be administered in powder form. The quality insurance and 
stability of the products in the pharmaceutical fi eld have gained considerable att ention in the last decades. Due to this fact, the aim was 
to execute a long-term stability study of a previously developed, nanosized lamotrigine (LAM) containing nasal powder (NP) formula-
tion. The results of the stability test showed that the NP formulation preserved its key properties (particle size, morphology, structure 
and in vitro drug release) after 6 months of storage.
Keywords: nasal delivery, stability test, nanotechnology, nasal powder, lamotrigine
DOI:  10.33892/aph.2020.90.27-31
1. Introduction
The nose off ers a great possibility to avoid adverse 
events and increase patient compliance[1–4]. Due 
to its advantageous properties local, systemic and 
central nervous (CNS) system eff ects are also 
available [5–7]. The application of innovative and 
effi  cient products, that are containing nanoparti-
cles, may lead to the improvement of diff erent 
therapies [8,9]. The quality insurance of pharma-
ceutical products has received considerable att en-
tion in the past few years. That is why the stability 
of the formulations has become extremely impor-
tant and therefore, quality infl uencing parameters 
need to be kept constant during the transport, 
storage, and application. Generally, solid dosage 
forms (e.g. nasal powders) have bett er stability 
than liquid formulations [10–12].
In our previous studies, a nanosized lamotrigi-
ne (LAM) containing nasal powder (NP) product 
was researched and developed. The investigations 
of the product showed that due to the eff ect of 
milling, the nanosized LAM particles became 
partly amorphous and distributed homogenously 
on the polymer, polyvinyl alcohol (PVA) matrix. 
Moreover, the product performed rapid and high 
amount of drug release in vitro and in vivo. This 
study aimed to carry out the long-term stability 
study of the previously developed NP formula-
tion, which contained nanosized LAM [13–15].
2. Materials and methods
2.1. Materials
Lamotrigine, poorly water-soluble (0.17 mg/mL at 
25 °C) was purchased from Teva Ltd. (Budapest, 
Hungary). PVA (Mw = 27,000), water-soluble syn-
thetic polymer – that was applied to stabilize the 
unique drug particles, thus improving their ab-
sorption – was supplied by ISP Customer Service 
GmBH (Cologne, Germany).
2.2. Sample Preparation
PVA was used as an additive during the sample 
preparation process to maintain the stability and 
individuality of LAM particles. NP sample was 
produced as follows: 0.8 g PVA and 1 g LAM were 
mixed in a Turbula mixer (Turbula System Schatz ; 
Willy A. Bachofen AG Maschinenfabrik, Basel, 
Switz erland) using 60 rpm for 10 min. After mix-
ing, the sample was placed into a planetary ball 
mill (Retsch PM 100; Retsch, Neuhausen, Germa-
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ny) and milled in a 50 mL capacity milling cham-
ber for 1.5 h on 400 rpm with 10 steel balls (diame-
ter 10 mm, the weight of each ball 4.02 g). In the 
case of the physical mixture (PM), PVA was milled 
for 1.5 h on 400 rpm and then—according to our 
previous experiments—it was mixed with un-
milled LAM using the same Turbula mixer for 10 
min on 60 rpm.
2.3. Circumstances of the stability
Stability tests were performed according to the 
ICH Q1A guideline [16] in Binder KBF 240 (Bind-
er GmbH, Tutt lingen, Germany) equipment, with 
a constant-climate chamber. An electronically 
controlled APT.lineTM line preheating chamber 
and refrigerating system ensured temperature 
accuracy and reproducibility of the results in the 
temperature range between 10 and 70 °C and the 
relative humidity (RH) range between 10 and 
80%. The stability test was performed at 25 ± 2 °C 
with 50 ± 5% RH (room conditions). Samples 
were kept in a closed jar during the tested peri-
od. Sampling was carried out after 1 day; 3 and 6 
months.
2.4. Particle size and morphology characterization
The particle size of the microparticles was charac-
terized by using Leica Image Processing and 
Analysis System device (Leica Q500MC; Leica Mi-
crosystems, Wetz lar, Germany). The test parame-
ters of 300 particles were their length, width, area, 
and district/convex perimeter.
The morphology and the size the LAM nano-
particles – that were on the surface of the polymer 
microparticles – were investigated by SEM (Hita-
chi S4700; Hitachi Ltd., Tokyo, Japan) at 10 kV. 
The samples were gold–palladium-coated (90 s) 
with a sputt er coater (Bio-Rad SC502; VG Micro-
tech, Uckfi eld, UK) using an electric potential of 
2.0 kV at 10mA for 10 min. The air pressure was 
1.3–13.0 mPa. Distribution of LAM particle diame-
ter was obtained by analyzing SEM images with 
the ImageJ software (1.50i; Java 1.6.0_20 [32-bit]; 
Windows NT) environment using approximately 
500 particles [17]. 
Statistical analysis was performed with TIBCO 
Statistica® 13.4 (Statsoft Hungary, Budapest, Hun-
gary). All reported data are means ± SD. The Stu-
dent’s t-test was used to determine the statistical 
signifi cance. Changes were considered statistically 
signifi cant at p < 0.05.
2.5. Structural investigations
2.5.1. Thermoanalytical measurements
The Mett ler Toledo TGA/DSC 1 thermal analysis 
system (Mett ler-Toledo GmbH, Greifensee, Swit-
zerland) was applied to characterize the struc-
tures of the products. The DSC (diff erential scan-
ning calorimetry) and TG (thermogravimetry) 
measurements were made by examining approxi-
mately 3-5 mg of samples in the temperature 
range between 25 ˚C and 230 ˚C at a heating rate of 
5 °C/min under constant argon fl ow of 150 mL/min 
and nitrogen fl ow of 50 mL/min. Data analysis 
was performed using the STARe software (Met-
tler-Toledo GmbH, Greifensee, Switz erland). The 
cristallinity indexes were calculated based on the 
ratio Normalized integrals, where the PM samples 
was considered as 100%.
2.5.2. X-ray powder diff raction (XRPD)
The XRPD measurement was carried out with a 
BRUKER D8 advance X-ray powder diff ractome-
ter (Bruker AXS GmbH, Karlsruhe, Germany) 
with Cu K λI radiation (λ=1.5406 Å) and a VÅN-
TEC-1 detector (Bruker AXS GmbH, Karlsruhe, 
Germany). The powder samples were loaded in 
contact with a plane quartz  glass sample slide 
with an etched square and measured. Samples 
were scanned at 40 kV and 40 mA. The angular 
range was 3°–40° 2θ, at a step time of 0.1 seconds 
and a step size of 0.007°. All manipulations, in-
cluding Kα2 stripping, background removal and 
smoothing of the area under the peaks of the dif-
fractograms, were performed using the DIF-
FRACplus EVA software. The crystallinity index 
(Xc) values were calculated based on the follow-
ing formule, where A marks the area under the 
whole curve:
Xc= Acrystalline/ (Acrystalline + Aamorphous) *100
PM sample was considered as 100%.
2.6. In vitro release study
The modifi ed paddle method (USP dissolution ap-
paratus, type II; Pharma Test, Hainburg, Germa-
ny) was used to examine the dissolution rate of 
LAM-containing co-milled nasal powders and de-
termine the drug release profi le from the samples. 
The test was carried out under nasal conditions 
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for temperature and pH. 100 ml phosphate-buff -
ered saline solution (PBS of pH 5.60 at 30 °C) was 
used as a medium in 150 mL vessels, in which 108 
mg of the samples were tested. The paddle was 
placed to halfway through the medium and was 
rotated at 50 rpm, and the sampling points were at 
5 min, 10 min, 15 min, 30 min, 45 min, and 60 min. 
In each sampling point 2 mL samples were taken, 
which volume was immediately replaced with 
fresh buff er solution to maintain the permanent 
volume. Cellulose ester membranes with 0.45 μm 
pore diameter was used for fi ltration. The sam-
pling points were more frequent in the beginning 
of the investigation as the mucociliary clearance 
renews the mucus every 15 min. The following 
sampling points off ered extra information about 
the dissolution behavior of LAM. After fi ltration, 
the drug content of the aliquots was determined 
using spectrophotometry (Unicam UV/VIS Spec-
trophotometer) at 307 nm. The tests were carried 
out in triplicates.
3. Results and discussion
3.1. Characterization of particle size and morphology
The results of particle size determination resulted 
in same particle size of the product during the ex-
amined period (Table 1), which 
shows that the product’s particles 
did not aggregate. The size falls 
into the range which is desired in 
the case of nasal powders, which 
is 10-40 μm [17].
The particle size of LAM in the 
formulation showed an increase 
with relatively high standard de-
viation, which is related to the na-
noscale range and the ImageJ 
technique used (Table 2). However, according to re-
sults of the statistical analysis there is no signifi -
cant diff erence in the particle sizes during the stor-
age period, thus the previously experienced rapid 
and high degree of release can be predicted.
The SEM pictures confi rm the results of the particle 
size determination as the nanosized LAM particles can 
be seen on the PVA surface in a homogenous distribu-
tion and showed no sign of aggregation during the test-
ed period (Figure 1). 
3.2. Structural investigations
The DSC curves (Figure 2A) in the tested period 
shows that the partly amorphous property of the 
sample did not change considerably. The melting 
point of LAM was between 216 °C and 217 °C, 
which became lower (~ 204 °C) due to the eff ect of 
milling and the presence of PVA. The two melting 
points merged as LAM melted on ~204 °C, while 
PVA did it on ~210 °C. However, the character and 
area of the endothermic peak are almost the same 
in each sampling point in the case of the NP for-
mulation. Compared to the PM, which was re-
garded as 100%, the crystallinity degrees of the 
samples were between 42 and 48%.
This immutability can be seen in the case of 
XRPD diff ractograms (Figure 2B). According to the 
Table 1 The results of particle size investigation of the product. 
Average size of the product (μm) t-value p-value Signifi cance
1-day 29.91±15.85 -0.1435 0.8883 n.s.
3 months 28.48±12.81 0.2994 0.7690 n.s.
6 months 26.52±11.14 0.9064 0.3801 n.s.
In the table n.s means that there is no signifi cant difference at 95% level.
Table 2 The results of particle size investigation of LAM. 
Average size of LAM (nm) t-value p-value Signifi cance
1-day 97±60 1.2382 0.2347 n.s.
3 months 105±77 0.7934 0.4408 n.s.
6 months 120± 84 -0.0408 0.9687 n.s.
In the table n.s means that there is no signifi cant difference at 95% level.
Figure 1 The SEM pictures of the NP samples
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diff ractograms, the characteristic 
2θ° values of the raw LAM were 
at 12.57, 19.62, 27.04, 27.19 and 
28.92 [13], which can be also seen 
in the case of the PM. Due to the 
co-milling with PVA, the crystal-
linity of the LAM decreased as the 
intensity of the characteristic 
peaks decreased in the 1-day sam-
ple. After 6 months, this de-
creased crystallinity was main-
tained. The crystallinity index 
was found 47.58% in the 1-day 
sample, which value did not 
change considerably during the 
storage. 
Table 3 shows the crystallinity 
index values of the samples. The 
results of the measurement con-
fi rmed the DSC results, which 
means that the LAM became and 
remained partly amorphous due 
to the milling eff ect and the pres-
ence of PVA in the tested period. 
Moreover, the TG results showed 
no change in mass, which refers 
that no dehydration or decompo-
sition occurred during the investi-
gation.
3.3. In vitro release study
In Figure 3, it can be seen that the 
LAM from the surface of the poly-
mer released rapidly in a high 
amount in the case of the NP 
sample compared to the PM and 
raw LAM. This rapid release was 
maintained during the examined 
period as practically there is no 
diff erence between the samples. 
The rapid dissolution rate was oc-
curred due to the nanosized prop-
erty of LAM and the presence of 
PVA.
4 . Conclusion
To conclude the study, it can be said that the key 
properties of the NP product did not change con-
siderably. The particle size of the product did not 
show relevant change during the tested period, 
while the particle size of LAM in the formulation 
Table 3 The crystallinity index (Xc) values of the samples
Xc (%)
DSC XRPD
PM 100 100
1-day 41.91 47.58
6 months 47.53 48.40
Figure 2 The DSC curves (A) and the XRPD diffractograms (B) of the samples
Figure 3 The results of the release study, where LAM is the raw lamotrigine and 
PM is the Physical Mixture
A
B
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showed an increase with no signifi cant diff erence. 
Moreover, the partly amorphous property of LAM 
was maintained during the stability test and ac-
cording to the TG results, no dehydration or de-
composition occurred, which suggests that the 
sample did not remove water from its surround-
ings during storage. The results of the dissolution 
studies showed a rapid and high amount of the re-
leased drug in the examined period. The results 
predict that PVA could prevent the particles from 
aggregation and recrystallization. However, fur-
ther stability investigations are required – accord-
ing to ICH guidelines –, but it they will be worth 
carrying out in a fi nal package. According to this 
study, it is predictable that the product can main-
tain its quality over a long period and thus to pro-
duce a proper eff ect.
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